Healthcare -
Biotechnology - NASDAQ - CN
$ 1.85
-4.64 %
$ 69.7 M
Market Cap
-2.5
P/E
1. INTRINSIC VALUE
Balance Sheet
Adagene Inc.
| Current Assets | 87.8 M |
| Cash & Short-Term Investments | 85.2 M |
| Receivables | 8.31 K |
| Other Current Assets | 2.58 M |
| Non-Current Assets | 1.51 M |
| Long-Term Investments | 0 |
| PP&E | 1.41 M |
| Other Non-Current Assets | 104 K |
| Current Liabilities | 38.2 M |
| Accounts Payable | 4.24 M |
| Short-Term Debt | 17.9 M |
| Other Current Liabilities | 16 M |
| Non-Current Liabilities | 560 K |
| Long-Term Debt | 560 K |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Adagene Inc.
| Revenue | 103 K |
| Cost Of Revenue | 926 K |
| Gross Profit | -823 K |
| Operating Expenses | 36.1 M |
| Operating Income | -36 M |
| Other Expenses | -2.53 M |
| Net Income | -33.4 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Adagene Inc.
| Net Income | -33.4 M |
| Depreciation & Amortization | 926 K |
| Capital Expenditures | -33.6 K |
| Stock-Based Compensation | 4.91 M |
| Change in Working Capital | -1.89 M |
| Others | -3.47 M |
| Free Cash Flow | -29.7 M |
Wall Street Analysts Price Targets
Adagene Inc.
Wall Street analysts predict an average 1-year price target for ADAG of $5 , with forecasts ranging from
a
low of
$5 to a high of $5 .
ADAG Lowest Price Target
Wall Street Target
5 USD
170.27%
ADAG Average Price Target
Wall Street Target
5 USD
170.27%
ADAG Highest Price Target
Wall Street Target
5 USD
170.27%
4. DIVIDEND
ANALYSIS
ADAG does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Adagene Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Adagene announces up to $25 million strategic investment from Sanofi
- Sanofi to exercise option on third SAFEbody discovery program and sponsor combination clinical trial with muzastotug
globenewswire.com
- 2 weeks ago
Adagene to Present at Jefferies Global Healthcare Conference 2025
SAN DIEGO and SUZHOU, China, May 27, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene's Chief Strategy Officer, Mickael Chane-Du, will participate in one-on-one investor meetings and a fireside chat at the Jefferies Global Healthcare Conference 2025, taking place June 3-5 in New York, New York.
globenewswire.com
- 1 month ago
Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting
CTLA-4 inhibitor ADG126 can be dosed at 20 mg/kg Q6W in combination with pembrolizumab with
globenewswire.com
- 1 month ago
Adagene Appoints John Maraganore, Ph.D. as Executive Advisor
- Biotech luminary to mentor C-suite and provide strategic guidance - SAN DIEGO and SUZHOU, China, April 28, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Dr. John Maraganore as Executive Advisor. “Adagene is currently breaking a toxicity barrier with their proprietary masking technology, delivering a checkpoint inhibitor selectively and conditionally to tumor cells.
globenewswire.com
- 2 months ago
Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting
SAN DIEGO and SUZHOU, China, April 23, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a poster presentation at ASCO 2025 in Chicago, IL, May 30 - June 3.
globenewswire.com
- 2 months ago
Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update
Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial responses
globenewswire.com
- 3 months ago
Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit
SAN DIEGO and SUZHOU, China, March 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its presentation at the 11th Annual Immuno-Oncology 360⁰ Summit in Boston on March 26, 2025. The summit, designed for all-size pharma/biotech companies, academia and investors seeking to enable a patient's immune system to eradicate cancer, provides the opportunity to hear directly from science and business stakeholders on the latest data impacting the field of immuno-oncology.
globenewswire.com
- 4 months ago
Adagene to Present at Leerink's Global Healthcare Conference 2025
SAN DIEGO and SUZHOU, China, March 06, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene's Chairman, Chief Executive Officer and President of R&D, Peter Luo, Ph.D., will participate in one-on-one investor meetings and provide a corporate update at Leerink's Global Healthcare Conference 2025, taking place March 10-12 in Miami, Florida.
globenewswire.com
- 4 months ago
Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer
- Trial to begin enrolling in April; expected primary completion in mid-2027 - - Primary study endpoint of rate of major pathological response - SAN DIEGO and SUZHOU, China, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced an investigator initiated (IIT) Phase 2 neoadjuvant trial of ADG126 for patients with stage II or stage III colorectal cancer. The new study (NCT06846268), led by primary investigator Dr. Yong Wei Peng, Senior Consultant at the Department of Haematology-Oncology, National University Cancer Institute, Singapore, is expected to begin patient enrollment in April 2025.
globenewswire.com
- 4 months ago
CD47 Inhibitor Drug Clinical Trials Market Opportunity Outlook 2028, Competitive Analysis of Adagene, ALX, ImmuneOncia, ImmuneOnco, Light Chain Bioscience, Phanes, and Virtuoso,
Dublin, Jan. 29, 2025 (GLOBE NEWSWIRE) -- The "Global CD47 Inhibitor Drug Clinical Trials Insight & Market Opportunity Outlook 2028" report has been added to ResearchAndMarkets.com's offering.
globenewswire.com
- 5 months ago
Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium
SAN DIEGO and SUZHOU, China, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced it will share updated clinical data from ADG126 in microsatellite stable colorectal cancer (MSS CRC) at the ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA on Saturday, January 25, 2025.
globenewswire.com
- 5 months ago
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
Here is how Adagene Inc. Sponsored ADR (ADAG) and Editas Medicine (EDIT) have performed compared to their sector so far this year.
zacks.com
- 6 months ago
8. Profile
Summary
Adagene Inc. ADAG
COUNTRY
CN
INDUSTRY
Biotechnology
MARKET CAP
$ 69.7 M
Dividend Yield
0.00%
Description
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Contact
Building C14, Suzhou, 215123
https://www.adagene.com
IPO
Date
Feb. 9, 2021
Employees
138
Officers
Dr. Jiping Zha M.D., Ph.D.
Executive Vice President of Clinical Development
Ms. Yan Li M.B.A.
Senior Vice President of Bioinformatics & Information Technology
Dr. Guizhong Liu Ph.D.
Senior Vice President of Early Drug Discovery
Ms. Ling Zhou
Executive Director & Head of Human Resources
Mr. Alexander Goergen
Vice President & Head of Business Development
Dr. Qinghai Zhao Ph.D.
Chief Manufacturing Officer
Ms. Xiaohong She
Senior Vice President & Head of Clinical Operations
Dr. Songmao Zheng Ph.D.
Senior Vice President of Clinical Pharmacology & Quantitative Sciences
Dr. Peter P. Luo Ph.D.
Co- Founder, Chairman, Chief Executive Officer and President of R&D
Mr. Man Kin Tam M.B.A.
Chief Financial Officer & Director